Skip to the page content
Your donations
Passes our checks

Phare Bio Inc

EIN 85-1085804 · Boston, MA

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthGood78 out of 100GovernanceStrong100 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

PHARE BIO'S MISSION IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. USING NOVEL AI AND DEEP LEARNING APPROACHES, PHARE BIO AIMS TO RAPIDLY DISCOVER AND DEVELOP NEW CLASSES OF ANTIBIOTICS AGAINST THE DEADLIEST PATHOGENS, AND ENSURE THAT THESE THERAPIES REACH THE PATIENTS IN GREATEST NEED.

Income
$5.5 million
Spending
$4.8 million
Spent on programs
85%
Reserves
8.1 months of spending
Largest source of income
fees for its services, 55%
Employees
3
Volunteers
7
Highest pay
$607,888, ceo & president

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Good: 78 out of 100. Higher than 42% of charities in its peer group (medical research, $1m to $10m).

  • Reserves

    28 of 35

    Spendable reserves would cover 8.1 months of spending.

  • Debt

    5 of 20

    It owes 54% of what it owns.

  • Living within its means

    15 of 15

    Income exceeded spending by 13% of income.

  • Income trend

    15 of 15

    Income rose 155% on the year before.

  • Spending floor

    15 of 15

    85% of spending went to programs and raising each dollar of donations cost 8 cents.

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Strong: 100 out of 100. Higher than 63% of charities in its peer group (medical research, $1m to $10m).

  • Independent board

    25 of 25

    6 of 7 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    8 of 8

    Has a written whistleblower policy.

  • Record keeping policy

    7 of 7

    Has a written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (1)
  1. $4.0 million spent. PHARE BIO'S PROGRAM MANDATE IS TO DEVELOP CRITICALLY NEEDED ANTIBIOTICS TO ADDRESS A LOOMING CRISIS IN ANTIBIOTIC RESISTANCE. PHARE BIO HAS A NUMBER OF PROMISING EARLY-STAGE PIPELINE PROJECTS AND IS CONDUCTING EXTENSIVE IN VITRO AND IN VIVO DRUG DEVELOPMENT STUDIES TO ADVANCE POTENTIAL ANTIBIOTICS THROUGH THE RESEARCH AND DEVELOPMENT PROCESS. THESE ANTIBIOTIC CANDIDATES ARE DISCOVERED USING NOVEL AI/DEEP LEARNING METHODOLOGIES PIONEERED BY PROFESSOR JIM COLLINS' LAB AT MIT (PHARE BIO'S CO-FOUNDER), AND ARE DEVELOPED AND OPTIMIZED BY PHARE BIO FOR FUTURE CLINICAL APPLICATION. WITH THIS CUTTING-EDGE PLATFORM AND A NONPROFIT BUSINESS MODEL, PHARE BIO IS DEVELOPING NEW CLASSES OF ANTIBIOTICS AND UNIQUELY ADDRESSING ECONOMIC CHALLENGES FACING THE ANTIBIOTIC MARKET. IN THIS PAST YEAR, PHARE BIO DISCOVERED AND STUDIED ADDITIONAL NOVEL ANTIBIOTICS WITH ITS GENERATIVE AI DRUG DESIGN PLATFORM, FURTHER ADVANCING ITS EARLY-STAGE PIPELINE.

Source: Form 990 for the year ending June 30, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated September 30, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated September 10, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending June 2025.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since December 2020.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 7, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.